Dimensional Fund Advisors LP Buys 58,954 Shares of Bioventus Inc. (NYSE:BVS)

Dimensional Fund Advisors LP lifted its holdings in Bioventus Inc. (NYSE:BVS - Free Report) by 100.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 117,496 shares of the company's stock after purchasing an additional 58,954 shares during the quarter. Dimensional Fund Advisors LP owned 0.15% of Bioventus worth $676,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. LSV Asset Management acquired a new position in shares of Bioventus during the 1st quarter worth approximately $1,170,000. American Century Companies Inc. increased its holdings in Bioventus by 289.5% during the second quarter. American Century Companies Inc. now owns 169,161 shares of the company's stock worth $973,000 after buying an additional 125,736 shares during the last quarter. Panagora Asset Management Inc. bought a new stake in Bioventus during the second quarter worth $787,000. Kennedy Capital Management LLC lifted its stake in Bioventus by 66.8% in the first quarter. Kennedy Capital Management LLC now owns 120,134 shares of the company's stock valued at $625,000 after acquiring an additional 48,111 shares during the last quarter. Finally, Bank of New York Mellon Corp bought a new position in shares of Bioventus in the 2nd quarter valued at about $647,000. Institutional investors and hedge funds own 62.94% of the company's stock.

Bioventus Stock Performance

BVS traded up $0.44 on Monday, reaching $12.57. The company had a trading volume of 390,401 shares, compared to its average volume of 393,315. The stock has a market cap of $995.12 million, a P/E ratio of -35.91 and a beta of 0.90. The company has a debt-to-equity ratio of 1.82, a quick ratio of 0.96 and a current ratio of 1.33. Bioventus Inc. has a fifty-two week low of $2.88 and a fifty-two week high of $12.68. The company's fifty day moving average is $10.23 and its 200 day moving average is $7.39.

Bioventus (NYSE:BVS - Get Free Report) last posted its earnings results on Tuesday, August 6th. The company reported $0.19 EPS for the quarter, beating the consensus estimate of $0.07 by $0.12. The company had revenue of $151.22 million for the quarter, compared to the consensus estimate of $137.70 million. Bioventus had a positive return on equity of 14.39% and a negative net margin of 7.82%. During the same quarter in the prior year, the business earned $0.14 earnings per share. As a group, analysts predict that Bioventus Inc. will post 0.4 earnings per share for the current fiscal year.

Insider Activity

In other Bioventus news, Director John A. Bartholdson purchased 80,000 shares of the stock in a transaction that occurred on Friday, August 16th. The shares were acquired at an average cost of $8.55 per share, with a total value of $684,000.00. Following the completion of the transaction, the director now owns 6,913,857 shares in the company, valued at $59,113,477.35. The trade was a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director John A. Bartholdson bought 25,500 shares of the business's stock in a transaction dated Monday, August 19th. The stock was purchased at an average cost of $8.55 per share, for a total transaction of $218,025.00. Following the transaction, the director now owns 6,939,357 shares in the company, valued at $59,331,502.35. The trade was a 0.00 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director John A. Bartholdson bought 80,000 shares of the firm's stock in a transaction on Friday, August 16th. The stock was purchased at an average cost of $8.55 per share, for a total transaction of $684,000.00. Following the completion of the acquisition, the director now owns 6,913,857 shares in the company, valued at approximately $59,113,477.35. This trade represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 32.90% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

BVS has been the topic of a number of recent analyst reports. Canaccord Genuity Group boosted their price target on Bioventus from $8.00 to $12.00 and gave the stock a "buy" rating in a research report on Tuesday, August 13th. Craig Hallum increased their price target on Bioventus from $12.00 to $17.00 and gave the company a "buy" rating in a research note on Friday, September 27th.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.